// App-Quantinova.ai

1494 : Combination of CEA TCB, a novel T-cell bispecific antibody for the treatment of solid tumors, with PD-L1 checkpoint blockade

Researchers

Presenter

  • Marina Bacac

Principal Investigators

  • Tanja Fauti

  • Sara Colombetti

  • Linda Fahrni

  • Valeria Nicolini

  • Christian Gerdes

  • Jose Saro

  • Vaios Karanikas

  • Christian Klein

  • Pablo Umana

Medical Centers

  • Roche Innovation Center Zurich, Schlieren, Switzerland

Locations

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 2AP

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Pyruvate Kinase M1/2

Drug/Treatment

  • Interferon Gamma

  • RO6958688

  • RG7802

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved